Citations

Clear

3942 citation(s) found for "To, Van".

Interobserver variation in the classification of thymic lesions including biopsies and resection specimens in an international digital microscopy panel
Wolf, Janina , Nederveen, Francien van, Blaauwgeers, Hans, Marx, Alexander, Nicholson, Andrew G. , Roden, Anja C. , Stroebel, Philipp, Timens, Wim , Weissferdt, Annikka , Bakker, Marina, den Bakker, Michael A , Timens, Wim , Nicholson, Andrew , Nederveen, Francien van, Blaauwgeers, Hans, Marx, Alexander, Thüsen, Jan H. von der

Mayo Clinic

Histopathology | June 7, 2020 | Volume: 77 | Issue: 5 | Pages: 734-741

10.1111/his.14167 | PMID 32506527 Get It

AimsThymic tumours are rare in routine pathology practice. Although the World Health Organization (WHO) classification describes a number of well‐defined categories, the classification remains challenging. The aim of this study was to investigate the reproducibility of the WHO classification among a large group of international pathologists with expertise in thymic pathology and by using whole slide imaging to facilitate rapid diagnostic turnover.Methods and resultsThree hundred and five tumours, consisting of 90 biopsies and 215 resection specimens, were reviewed with a panel‐based virtual microscopy approach by a group of 13 pathologists with expertise in thymic tumours over a period of 6 years. The specimens were classified according to the WHO 2015 classification. The data were subjected to statistical analysis, and interobserver concordance (Fleiss kappa) was calculated. All cases were diagnosed within a time frame of 2 weeks. The overall level of agreement was substantial (κ = 0.6762), and differed slightly between resection specimens (κ = 0.7281) and biopsies (κ = 0.5955). When analysis was limited to thymomas only, and they were grouped according to the European Society for Medical Oncology Clinical Practice Guidelines into B2, B3 versus A, AB, B1 and B3 versus A, AB, B1, B2, the level of agreement decreased slightly (κ = 0.5506 and κ = 0.4929, respectively). Difficulties arose in distinguishing thymoma from thymic carcinoma. Within the thymoma subgroup, difficulties in distinction were seen within the B group.ConclusionsAgreement in diagnosing thymic lesions is substantial when they are assessed by pathologists with experience of these rare tumours. Digital pathology decreases the turnaround time and facilitates access to what is essentially a multinational resource. This platform provides a template for dealing with rare tumours for which expertise is sparse.
LB002ILLUMINATE-A, A PHASE 3 STUDY OF LUMASIRAN, AN INVESTIGATIONAL RNAI THERAPEUTIC, IN CHILDREN AND ADULTS WITH PRIMARY HYPEROXALURIA TYPE 1 (PH1)
Frishberg, Yaacov, Hulton, Sally A., Koren, Michael J. , O’Riordan, William, Cochat, Pierre , Shasha‐Lavsky, Hadas , Saland, Jeffrey M. , Hoff, William van’t , Magen, Daniella , Moochhala, Shabbir H. , Schalk, Gesa, Šimková, Eva, Groothoff, Jaap W. , Sas, David J. , Meliambro, Kristin, Lu, Jiandong , Garg, Pushkal, Gansner, John M. , McGregor, Tracy L., Garrelfs, Sander F. , Deschênes, Georges , Fuster, Daniel Guido , Lieske, John C.

Mayo Clinic

Nephrology Dialysis Transplantation | June 7, 2020 | Volume: 35 | Issue: Supplement_3 | Pages: No page available

10.1093/ndt/gfaa146.lb002 Get It

Abstract Background and Aims PH1 is a rare genetic disorder characterized by hepatic oxalate overproduction, leading to recurrent kidney stones, nephrocalcinosis, progressive kidney failure, and multiorgan damage from systemic oxalosis. There are no approved pharmacologic therapies for PH1. Lumasiran is a subcutaneously-administered investigational RNAi therapeutic that targets glycolate oxidase to reduce hepatic oxalate production. We report the first results from the six-month, double-blind period of ILLUMINATE-A, a randomized, placebo-controlled Phase 3 study to evaluate lumasiran in patients with PH1. Method Key inclusion criteria: age≥6 years, 24hr urinary oxalate (UOx)≥0.70 mmol/24hr/1.73m2, confirmed PH1 diagnosis, eGFR≥30 mL/min/1.73m2. Randomization: 2:1; lumasiran (n=26), placebo (n=13). Dosing: 3 mg/kg monthly×3, then quarterly. Primary endpoint: percent change in 24hr UOx excretion from baseline to month (M) 6. Primary comparison: least square (LS) mean treatment difference in percent change from baseline (average of M3-6). Results Lumasiran led to a statistically significant percent reduction in 24hr UOx excretion compared to placebo: the LS mean change from baseline to M6 (average of M3-6) was −65.4% with lumasiran and −11.8% with placebo (LS mean difference: −53.5%; p=1.7 × 10−14). Subgroup analyses of the primary endpoint showed a consistent effect of lumasiran across age, baseline UOx, eGFR, and concomitant pyridoxine use. Lumasiran led to statistically significant improvements in all hierarchically tested secondary endpoints, including: proportion of lumasiran-treated patients that achieved normalization or near-normalization of 24hr UOx at M6 (84% vs 0% of placebo-treated patients, p=8.3 × 10−7), and percent change in plasma oxalate from baseline to M6 (average of months 3-6) (-39.5%, p=2.9 × 10−8). There were no serious or severe adverse events. The most common adverse events related to lumasiran were mild, transient injection site reactions. Conclusion Lumasiran resulted in clinically meaningful, rapid, sustained, and statistically significant reductions in urinary and plasma oxalate levels compared to placebo during the six-month double-blind period. Lumasiran has a favorable safety profile.
Trends in the Incidence and Treatment of Distal Radius Fractures in the United States in Privately Insured and Medicare Advantage Enrollees
Kakar, Sanjeev , Noureldin, Mohamed , Houten, Holly K. Van , Mwangi, Raphael , Sangaralingham, Lindsey R. , Kakar, Sanjeev , Noureldin, Mohamed

Mayo Clinic

HAND | June 7, 2020 | Volume: 17 | Issue: 2 | Pages: 331-338

10.1177/1558944720928475 | PMID 32506961 Get It

Background: This study aims to determine the trends in the treatment of distal radius fractures (DRFs) in patients aged 18 years and older. Methods: An administrative claims database of more than 100 million patients was used to identify patients aged 18 years and older with a DRF between 2005 and 2014. A total of 137 130 DRFs were identified in 135 128 patients. Results: The proportion and rate of fractures were more predominant in those aged 55 years and older compared with a decreasing incidence in patients younger than 55 years. Age-adjusted rates of surgical treatment have significantly increased in both women and men by 15.9% (absolute change, 4.8%) and 5.0% (absolute change, 1.7%) change over time, respectively. Conversely, age-adjusted rates of nonsurgical treatment have significantly decreased overtime in both women and men by 6.9% and 2.6%, respectively. Conclusions: These data provide better understanding of the epidemiology of DRF, which is important to develop preventive strategies targeting high-risk populations and to develop effective treatment strategies.
P1799GENOTYPE-PHENOTYPE CORRELATION IN A PEDIATRIC ADPKD COHORT
Giel, Dorien Van , Breysem, Luc , Hindryckx, An , Decuypere, Jean-Paul , Corveleyn, Anniek , Audrézet, Marie‐Pierre , Rechter, Stéphanie De , Janssens, Peter , Bammens, Bert , Férec, Claude , Vennekens, Rudi , Harris, Peter C. , Mekahli, Djalila

Mayo Clinic

Nephrology Dialysis Transplantation | June 6, 2020 | Volume: 35 | Issue: Supplement_3 | Pages: No page available

10.1093/ndt/gfaa144.p1799 Get It

Abstract Background and Aims The correlation between genotype and phenotype is well described in ADPKD adults. PKD2 is milder than PKD1 disease, with end stage kidney disease (ESKD) occurring on average 20 years later, and patients with PKD1 truncating mutations having a more severe outcome than PKD1 non-truncating mutations. Still, large differences in outcome occur even within families carrying the same gene variation. Only a few cases series reported the genetic profile of severely affected ADPKD children and suggest an additional effect of hypomorphic genes. We therefore aim to analyse the geno-phenotype profile in a well characterized pediatric ADPKD cohort. Method Clinical, familial, biological and imaging data were collected longitudinally in children diagnosed with ADPKD. Genotypic analysis was done using a custom Agilent SureSelect gene panel containing 136 ciliopathy-associated genes, including PKD1 and PKD2. Mutations and/or variants identified were individually evaluated for pathogenicity. Results 57 ADPKD children from 44 families were diagnosed at a mean (± SD) age of 4.1 (±4.8) years. ADPKD diagnosis was made in 32 children (56%) because of asymptomatic screening as requested by the family; 7 (12%) due to presenting symptoms (6 due to urinary tract infection and 1 due to post-traumatic macroscopic hematuria); 9 (16%) due to a coincidental finding of renal cysts on US performed for another reason and in 9 cases (16%) a prenatal diagnosis was performed. Twenty-nine children (51%) met the definition of very-early onset (VEO) disease. We identified pathogenic mutations in 100% of our patients, in which the prevalence of PKD1 truncating, PKD1 non-truncating, PKD2 and GANAB mutations was 75%, 19%, 4%, and 2%, respectively. Four cases (7%) were due to a de novo mutation. Interestingly, in 29 patients (51%) the germline mutation was the only identified mutation. However, in the rest of the subjects additional variants were identified in other ciliopathy-associated genes. In 12 cases (21%) the additional identified variants found in either the PKD, PMM2, HNF1B, DNAJC1, CEP290, NEK1, MKKS, NPHP4 or PKHD1 genes were scored to have a potential phenotypic effect, which will be evaluated by continued follow-up of this cohort. Conclusion We report the first large cohort of genotyped ADPKD children, including an extensive panel of ciliopathy genes next to the PKD genes. Interestingly, we found a high prevalence of additional and potentially modifying variants in this young population.
The Diet of Higher Insulinemic Potential Is Not Associated with Worse Survival in Patients with Stage III Colon Cancer (Alliance)
Cheng, En , Zhang, Sui , Ou, Fang‐Shu , Mullen, Brian C, Ng, Kimmie , Niedzwiecki, Donna , Mowat, Rex B., Whittom, Renaud , Hantel, Alexander, Benson, Al B. , Atienza, Daniel, Messino, Michael J., Kindler, Hedy L. , Giovannucci, Edward L. , Blarigan, Erin L. Van , Meyerhardt, Jeffrey A. , Fuchs, Charles S. , Mullen, Brian, Saltz, Leonard , Whittom, Renaud , Van Blarigan, Erin L , Meyerhardt, Jeffrey A , Ou, Fang-Shu , Niedzwiecki, Donna , Saltz, Leonard B. , Mayer, Robert J. , Cheng, En

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | June 4, 2020 | Volume: 29 | Issue: 8 | Pages: 1692-1695

10.1158/1055-9965.epi-19-1454 | PMID 32499312 Get It

Abstract Background: Hyperinsulinemia is considered to be important in the development of colon cancer, but few studies have investigated the associations of hyperinsulinemia with colon cancer survival via dietary scores. Methods: Empirical dietary index for hyperinsulinemia (EDIH) was derived to assess the insulinemic potential of daily diets reflecting the long-term insulin exposure, with higher (more positive) scores indicating higher insulinemic diets. We prospectively estimated the HRs and 95% confidence intervals (CI) to investigate the association of EDIH with disease-free, recurrence-free, and overall survival among patients with stage III colon cancer (1999–2009) enrolled in a randomized adjuvant chemotherapy trial (CALGB 89803). Results: Of 1,024 patients (median follow-up: 7.3 years), 311 died, 350 had recurrences, and 394 had events for disease-free survival. Compared with patients in the lowest quintile of EDIH, the corresponding HRs of patients in the highest quintile for disease-free survival events, cancer recurrence, and overall mortality were 0.80 (95% CI, 0.56–1.15), 0.76 (95% CI, 0.51–1.11), and 0.77 (95% CI, 0.52–1.14). Conclusions: Higher EDIH was not associated with the risk of colon cancer recurrence or mortality in this population of patients with stage III colon cancer. Impact: EDIH, as a measure of dietary insulinemic potential, may be associated with colon cancer risk but not survival in patients with late-stage colon cancer.
Aminoglycosides in Immunocompromised Critically Ill Patients With Bacterial Pneumonia and Septic Shock: A Post-Hoc Analysis of a Prospective Multicenter Multinational Cohort
López, René , Salem, Omar Ben Hadj , Seguin, Amélie, Louw, Andry Van de , Klouche, Kada , Martín‐Loeches, Ignacio , Mehta, Sangeeta , Bruneel, Fabrice , Lisboa, Thiago , Viana, William, Pickkers, Peter, Russell, Lene , Rusínová, Kateřina , Kouatchet, Achille, Barbier, François , Russell, Lene , Martin-Loeches, Ignacio , Rello, Jordi , Taccone, Fabio Silvio , Bauer, Philippe R. , Metaxa, Victoria , Montini, Luca , Mokart, Djamel , Azoulay, Élie , Darmon, Michaël

Mayo Clinic

Shock | June 3, 2020 | Volume: 54 | Issue: 6 | Pages: 731-737

10.1097/shk.0000000000001553 | PMID 32496415 Get It

ABSTRACT Background: The routine use of empiric combination therapy with aminoglycosides during critical illness is associated with uncertain benefit and increased risk of acute kidney injury. This study aimed to assess the benefits of aminoglycosides in immunocompromised patients with suspected bacterial pneumonia and sepsis. Methods: Secondary analysis of a prospective multicenter study. Adult immunocompromised patients with suspected bacterial pneumonia and sepsis or septic shock were included. Primary outcome was hospital mortality. Secondary outcomes were needed for renal replacement therapy (RRT). Mortality was also assessed in neutropenic patients and in those with confirmed bacterial pneumonia. Results were further analyzed in a cohort matched on risk of receiving aminoglycosides combination. Results: Five hundred thirty-five patients were included in this analysis, of whom 187 (35%) received aminoglycosides in addition to another antibiotic effective against gram-negative bacteria. Overall hospital mortality was 59.6% (58.3% vs. 60.3% in patients receiving and not receiving combination therapy; P = 0.71). Lack of association between mortality and aminoglycosides was confirmed after adjustment for confounders and center effect (adjusted OR 1.14 [0.69–1.89]) and in a propensity matched cohort (adjusted OR = 0.89 [0.49–1.61]). No association was found between aminoglycosides and need for RRT (adjusted OR = 0.83 [0.49–1.39], P = 0.477), nor between aminoglycoside use and outcome in neutropenic patients or in patients with confirmed bacterial pneumonia (adjusted OR 0.66 [0.23–1.85] and 1.25 [0.61–2.57], respectively). Conclusion: Aminoglycoside combination therapy was not associated with hospital mortality or need for renal replacement therapy in immunocompromised patients with pulmonary sepsis.
Consensus recommendations for a dynamic susceptibility contrast MRI protocol for use in high-grade gliomas
Boxerman, Jerrold L. , Quarles, C. Chad , Hu, Leland , Gerstner, Elizabeth R. , Smits, Marion , Barboriak, Daniel P. , Huang, Raymond, Wick, Wolfgang , Weller, Michael , Kalpathy–Cramer, Jayashree , Shankar, Lalitha , Jacobs, Paula , Chung, Caroline , Bent, Martin J. van den , Chang, Susan M. , Yung, Wai Kuen, Wen, Patrick Y. , Rosen, Bruce R. , Arons, David F., Kingston, Ann E, Sandak, David, Wallace, M. Z., Musella, Al , Haynes, Chas, Weller, Michael , van den Bent, Martin J , Boxerman, Jerrold L , Wick, Wolfgang , Smits, Marion , Barboriak, Daniel P , Erickson, Bradley J. , Kaufmann, Timothy J. , Galanis, Evanthia , Chang, Susan Marina , Yung, W K Al, Cloughesy, Timothy F. , Wen, Patrick Yung , Gilbert, Mark R. , Ellingson, Benjamin M. , Schmainda, Kathleen M

Mayo Clinic

Neuro-Oncology | June 3, 2020 | Volume: 22 | Issue: 9 | Pages: 1262-1275

10.1093/neuonc/noaa141 | PMID 32516388 Get It

Abstract Despite the widespread clinical use of dynamic susceptibility contrast (DSC) MRI, DSC-MRI methodology has not been standardized, hindering its utilization for response assessment in multicenter trials. Recently, the DSC-MRI Standardization Subcommittee of the Jumpstarting Brain Tumor Drug Development Coalition issued an updated consensus DSC-MRI protocol compatible with the standardized brain tumor imaging protocol (BTIP) for high-grade gliomas that is increasingly used in the clinical setting and is the default MRI protocol for the National Clinical Trials Network. After reviewing the basis for controversy over DSC-MRI protocols, this paper provides evidence-based best practices for clinical DSC-MRI as determined by the Committee, including pulse sequence (gradient echo vs spin echo), BTIP-compliant contrast agent dosing (preload and bolus), flip angle (FA), echo time (TE), and post-processing leakage correction. In summary, full-dose preload, full-dose bolus dosing using intermediate (60°) FA and field strength-dependent TE (40–50 ms at 1.5 T, 20–35 ms at 3 T) provides overall best accuracy and precision for cerebral blood volume estimates. When single-dose contrast agent usage is desired, no-preload, full-dose bolus dosing using low FA (30°) and field strength-dependent TE provides excellent performance, with reduced contrast agent usage and elimination of potential systematic errors introduced by variations in preload dose and incubation time.
Does pituitary compression/empty sella syndrome contribute to MRI-negative Cushing’s disease? A single-institution experience
Himes, Benjamin , Bhargav, Adip G. , Brown, Desmond , Kaufmann, Timothy J. , Bancos, Irina , Gompel, Jamie J. Van

Mayo Clinic

Neurosurgical Focus | June 3, 2020 | Volume: 48 | Issue: 6 | Pages: E3

10.3171/2020.3.focus2084 | PMID 32480375 Get It

OBJECTIVE Cushing’s disease arises from functioning adrenocorticotropic hormone (ACTH)–secreting pituitary adenomas. These tumors can be very small and evade detection by MRI. Empty sella syndrome is a phenomenon by which an arachnoid outpouching of CSF into the sella leads to compression of the pituitary, likely due to intracranial hypertension (a common issue in Cushing’s disease), further leading to difficulty in visualizing the pituitary gland that may contribute to difficulty in finding a tumor on MRI, so-called MRI-negative Cushing’s disease. The authors sought to examine the association between empty sella syndrome and MRI-negative Cushing’s disease. METHODS A single-institution database of Cushing’s disease cases from 2000 to 2017 was reviewed, and 197 cases were included in the analysis. One hundred eighty patients had a tissue diagnosis of Cushing’s disease and 17 had remission with surgery, but no definitive tissue diagnosis was obtained. Macroadenomas (tumors > 1 cm) were excluded. The degree of empty sella syndrome was graded on the degree of CSF visualized in the sella on midline sagittal T1-weighted MRI. RESULTS Of the 197 cases identified, 40 (20%) presented with MRI-negative disease, and empty sella syndrome was present in 49 cases (25%). MRI-negative disease was found in 18 (37%) of 49 empty sella cases versus 22 (15%) of 148 cases without empty sella syndrome present. Empty sella syndrome was significantly associated with MRI-negative disease (OR 3.32, 95% CI 1.61–6.74, p = 0.0018). Decreased thickness of the pituitary gland was also associated with MRI-negative disease (mean thickness 5.6 vs 6.8 mm, p = 0.0002). CONCLUSIONS Empty sella syndrome is associated with an increased rate of MRI-negative Cushing’s disease. Pituitary compression causing a relative reduction in the volume of the pituitary for imaging is a plausible cause for not detecting the tumor mass with MRI.
Hereditary Thrombotic Thrombocytopenic Purpura in a 9-Month-old: Diagnosing and Managing an Ultra-rare Disorder
Wyatt, Kirk D. , Kohorst, Mira A. , Coon, Lea M., Hurley, Rachel M. , Dorland, H.A. van , Arndt, Carola A.S.

Mayo Clinic

Journal of Pediatric Hematology/Oncology | June 2, 2020 | Volume: 43 | Issue: 4 | Pages: e577-e579

10.1097/mph.0000000000001830 | PMID 32496441 Get It

Hereditary thrombotic thrombocytopenic purpura is an ultra-rare disorder caused by biallelic mutations in the ADAMTS13 gene. Because it can be difficult to diagnose, plasma ADAMTS13 activity assessment should be considered in patients with thrombocytopenia, anemia, and schistocytes on peripheral blood smear. We present the diagnostic evaluation of a patient with hereditary thrombotic thrombocytopenic purpura. Genetic testing revealed one known pathogenic mutation and one novel mutation of ADAMTS13 classified as likely pathogenic on the basis of parental genetic testing and in silico analyses. We further discuss off-label use of prophylactic plasma-derived Factor VIII (Koate-DVI) and the benefit of rare disease registries.
Phage Therapy for Limb-threatening Prosthetic Knee Klebsiella pneumoniae Infection: Case Report and In Vitro Characterization of Anti-biofilm Activity
Caflisch, Katherine M., Patel, Robin , Fackler, Joseph , Brownstein, Michael, Horne, Bri’Anna , Biswas, Biswajit , Henry, Matthew, Malagón, Francisco , Lewallen, David G. , Cano, Edison J, Patel, Robin , Cevallos, Edison Cano , Bollyky, Paul L. , Belleghem, Jonas D. Van , Suh, Gina A.

Mayo Clinic

Clinical Infectious Diseases | June 1, 2020 | Volume: 73 | Issue: 1 | Pages: e144-e151

10.1093/cid/ciaa705 | PMID 32699879 Get It

Abstract Background Prosthetic joint infection (PJI) is a potentially limb-threatening complication of total knee arthroplasty. Phage therapy is a promising strategy to manage such infections including those involving antibiotic-resistant microbes, and to target microbial biofilms. Experience with phage therapy for infections associated with retained hardware is limited. A 62-year-old diabetic man with a history of right total knee arthroplasty 11 years prior who had suffered multiple episodes of prosthetic knee infection despite numerous surgeries and prolonged courses of antibiotics, with progressive clinical worsening and development of severe allergies to antibiotics, had been offered limb amputation for persistent right prosthetic knee infection due to Klebsiella pneumoniae complex. Intravenous phage therapy was initiated as a limb-salvaging intervention. Methods The patient received 40 intravenous doses of a single phage (KpJH46Φ2) targeting his bacterial isolate, alongside continued minocycline (which he had been receiving when he developed increasing pain, swelling, and erythema prior to initiation of phage therapy). Serial cytokine and biomarker measurements were performed before, during, and after treatment. The in vitro anti-biofilm activity of KpJH46Φ2, minocycline and the combination thereof was evaluated against a preformed biofilm of the patient’s isolate and determined by safranin staining. Results Phage therapy resulted in resolution of local symptoms and signs of infection and recovery of function. The patient did not experience treatment-related adverse effects and remained asymptomatic 34 weeks after completing treatment while still receiving minocycline. A trend in biofilm biomass reduction was noted 22 hours after exposure to KpJH46Φ2 (P = .063). The addition of phage was associated with a satisfactory outcome in this case of intractable biofilm-associated prosthetic knee infection. Pending further studies to assess its efficacy and safety, phage therapy holds promise for treatment of device-associated infections.